May 7, 2025

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics:

• Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00)
• CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06)
• Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17)
• Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34)
• Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41)
• ADCs for HER2-Positive Breast Cancer (46:30)
• HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26)
• ADCs for Advanced Triple-Negative Breast Cancer (58:29)

CME information and select publications